BCTX vs. UNCY, CUE, MRSN, IOBT, ACHL, OPTN, VOR, KRON, STTK, and CRVO
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Unicycive Therapeutics (UNCY), Cue Biopharma (CUE), Mersana Therapeutics (MRSN), IO Biotech (IOBT), Achilles Therapeutics (ACHL), OptiNose (OPTN), Vor Biopharma (VOR), Kronos Bio (KRON), Shattuck Labs (STTK), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.
BriaCell Therapeutics vs.
BriaCell Therapeutics (NASDAQ:BCTX) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.
In the previous week, BriaCell Therapeutics and BriaCell Therapeutics both had 1 articles in the media. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Unicycive Therapeutics'average media sentiment score.
Unicycive Therapeutics received 20 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 76.19% of users gave Unicycive Therapeutics an outperform vote.
15.4% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 5.7% of BriaCell Therapeutics shares are held by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
BriaCell Therapeutics has higher earnings, but lower revenue than Unicycive Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
BriaCell Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500.
BriaCell Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 615.88%. Unicycive Therapeutics has a consensus price target of $5.33, indicating a potential upside of 684.31%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than BriaCell Therapeutics.
Summary
Unicycive Therapeutics beats BriaCell Therapeutics on 11 of the 14 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCTX) was last updated on 3/24/2025 by MarketBeat.com Staff
